Video

Jessica Safran Provides Advice on Picking a Wig After Chemotherapy

Author(s):

Jessica Safran

Safran is the Executive Director of The Identity Shift Project, which aims to bring new perspectives to healing through collaborative art making.

Jessica Safran, a survivor of ovarian cancer and the Executive Director of The Identity Shift Project, tells of her adventure with wigs after receiving chemotherapy.

The Identity Shift Project brings new perspectives to healing through artistic collaboration with people experiencing significant life change. The project "provides people with a medium for creative exploration through which they can redefine their identity. Identity Shifts happen through a transformation and are integral to healing,” according to their website.

Related Videos
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with brown and grey hair.
Image of man with grey hair.
Image of bald man in suit.
Related Content
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The FDA has accepted an NDA for avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
January 2nd 2025

FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer

Ryan Scott
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY
May 4th 2023

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

Brielle Benyon
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
Julie S. Brokaw
December 26th 2024

Reflecting on 2024 Following an Ovarian Cancer Diagnosis

Julie S. Brokaw
Nearly 12 years after being diagnosed with ovarian cancer, Julie Brokaw believes life is a miracle.
Image of Jace.
December 24th 2024

Jace Yawnick of Jace Beats Cancer on the ‘Roller Coaster’ of Life in Remission

Alex Biese
After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.